Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease

Gut

Volumn 55, Issue 11, 2006, Pages 1650-1660

  Guha, I N ^a   Parkes, J ^a   Roderick, P R ^a   Harris, S ^a   Rosenberg, W M ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ALCOHOLIC FATTY LIVER; CLINICAL PRACTICE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; GENOMICS; HEPATIC VEIN; HEPATITIS C; HUMAN; INSULIN RESISTANCE; LIVER DISEASE; LIVER FIBROSIS; LIVER FUNCTION TEST; META ANALYSIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; RADIODIAGNOSIS; REVIEW; SYSTEMATIC REVIEW; THERAPY;

BIOLOGICAL MARKERS; FATTY LIVER; HUMANS; LIVER CIRRHOSIS; SEVERITY OF ILLNESS INDEX;

EID: 33750312195     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2006.091454     Document Type: Review

References (53)

1. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: Summary of an AASLD single topic conference. Hepatology 2003;37:1202-19.
2. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000;32:477-81.
3. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128:1898-906.
4. Scheuer PJ. Assessment of liver biopsies in chronic hepatitis: how is it best done? J Hepatol 2003;38:240-2.
5. Rosenberg WM. Rating fibrosis progression in chronic liver diseases. J Hepatol 2003;38:357-60.
6. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-21.
7. Adams LA, Sanderson S, Lindor KD, et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study or 103 patients with sequential liver biopsies. J Hepatol 2005;42:132-38.
8. Deeks JJ. Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests. BMJ 2001;323:157-62.
9. Haynes RB, Wilczynski NL. Optimal search strategies for retrieving scientifically strong studies of diagnosis from Medline: analytical survey. BMJ 2004;328:1040.
10. Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003;3:25.
11. Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356-62.
12. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004;127:1704-13.
13. Sakugawa H, Nakayoshi T, Kobashigawa K, et al. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatly liver disease. World J Gastroenterol 2005;11:255-9.
14. Albano E, Mottaran E, Vidali M, et al. Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut 2005;54:987-93.
15. Mofrad P, Contos MJ, Hoque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286-92.
16. Shimoda M, Hashimoto E, Kanada H, et al. Nonalcoholic steatohepatitis: Risk factors for liver fibrosis. Hepatol Res 2002;24:429-38.
17. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatly liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroentorology 2001;121:91-100.
18. Beymer C, Kowaley KV, Larson A, et al. Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. Arch Surg 2003;138:1240-4.
19. Bugianesi E, Manzini P, D'Antico S, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004;39:179-87.
20. Dixon JB, Bhathal PS, Jonsson JR, et al. Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. J Hepatol 2003;39:967-71.
21. Hui JM, Hodge A, Farrell GC, et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004;40:46-54.
22. Guidorizzi de Siqueira AC, Cotrim HP, Rocha R, et al. Non-alcoholic fatty liver disease and insulin resistance: importance of risk factors and histological spectrum. Eur J Gastroenterol Hepatol 2005;17:837-41.
23. Suzuki A, Angulo P, Lymp J, et al. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 2005;25:779-86.
24. Angulo P, Alba LM, Petrovic LM, et al. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol 2004;41:943-9.
25. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23.
26. Hashimoto E, Yatsuji S, Kaneda H, et al. The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. Hepatol Res 2005;33:72-6.
27. One JP, Elariny H, Collantes R, et al. Predictors of nonalcoholic steatohepatitis ana advanced fibrosis in morbidly obese patients. Obes Surg 2005;15:310-15.
28. Ledinghen LV, Combes M, Trouette H, et al. Should a liver biopsy be done in patients with subclinical chronically elevated transaminases? Eur J Gastroenterol Hepatol 2004;16:879-33.
29. Rotziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology 2000;118:1117-23.
30. Sorrentino P, Tarantino G, Conca P, et al. Silent non-alcoholic fatty liver disease-A clinical-histological study. J Hepatol 2004;41:751-7.
31. Crespo J, Fernandez-Gil P, Hernandez-Guerra M, et al. Are there predictive factors of severe liver fibrosis in morbidly obese patients with non-alcoholic steatohepatitis? Obes Surg 2001;11:254-7.
32. Fierbinteanu-Braticevici C, Bengus A, Neamtu M, et al. The risk factors of fibrosis in nonalcoholic steatohepatitis. Rom J Intern Med 2002;40:81-8.
33. Loguercio C, De Simone T, D'Auria MV, et al. Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian association for the study of the liver. Dig Liver Dis 2004;36:398-405.
34. dos Santos SV, Leite-Mor MMB, Kondo M, et al. Serum laminin, type IV collagen and hyaluronan as fibrosis markers in non-alcoholic fatty liver disease. Braz J Med Biol Res 2005;38:747-53.
35. Yesilova Z, Yaman H, Oktenli C, et al. Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:850-5.
36. Koruk M, Savas MC, Yilmaz O, et al. Serum lipids, lipoproteins and apolipoproteins levels in patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 2003;37:177-82.
37. Hartleb M, Kajor M, Gupinska-Kajor M, et al. Nonalcoholic fatty liver disease; who does not benefit from hepatic biopsy? Gastroenterol Polska 2005;12:209-13.
38. Chitturi S, Farrell G, Frost L, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? (Erratum appears in Hepatology 2002;36:1307.) Hepotology 2002;36:403-9.
39. Brunt EM, Neuschwander-Tetri BA, Oliver D, et al. Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. Hum Pathol 2004;35:1070-82.
40. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CUNIVIR, and DOSVIRC groups. Lancet 1997;349:825-32.
41. Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001;34:738-44.
42. Samuel VT, Liu ZX, Qu X, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004;279:32345-53.
43. Zeng MD, Lu LG, Mao YM, et al. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology 2005;42:1437-45.
44. Guechot J, Laudat A, Loria A, et al. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 1996;42:558-63.
45. Pares A, Deulofeu R, Gimenez A, et al. Serum hyaluronate reflects hepatic fibrogenesis In alcoholic liver disease and is useful as a marker of fibrosis. Hepatology 1996;24:1399-403.
46. Parkes JJ, Guha IN, Roderick P, et al. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol 2006;44:462-74.
47. Poynard T, Ratziu V, Naveau S, et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 2005;4:10.
48. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
49. Huang MA, Greenson JK, Chao C, et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol 2005;100:1072-81.
50. Dixon JB, Bhathal PS, Hughes NR, et al. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004;39:1647-54.
51. Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006;55:403-8.
52. Lim AK, Taylor-Robinson SD, Patel N, et al. Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. Gut 2005;54:128-33.
53. Younossi ZM, Baranova A, Ziegler K, et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 2005;42:665-74.